Henrique Vara Luiz1,2, Mary Jane Tanchee1,3, Maria G Pavlatou4, Run Yu5, Joan Nambuba1, Katherine Wolf1, Tamara Prodanov1, Robert Wesley6, Karen Adams1, Tito Fojo7, Karel Pacak1. 1. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 2. Department of Endocrinology and Diabetology, Hospital Garcia de Orta, Almada, Portugal. 3. Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, España, Manila, Philippines. 4. Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. 5. Division of Endocrinology and Carcinoid and Neuroendocrine Tumour Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6. Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA. 7. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
OBJECTIVE: Pharmacological treatment is mandatory in patients with hormonally functional phaeochromocytoma and paraganglioma (PHAEO/PGL). We evaluated if patients initially diagnosed with hormonally functional PHAEO/PGL by various medical subspecialties received proper adrenoceptor blockade, and analysed factors predicting the prescription of adequate treatment. METHODS: In a retrospective cohort study, we reviewed data from patients initially diagnosed with hormonally functional PHAEO/PGL outside the National Institutes of Health and Cedars-Sinai Medical Center, who were referred to these institutions between January 2001 and April 2015. Logistic regression was used to assess factors associated with proper adrenoceptor blockade. RESULTS: A total of 381 patients were included. Adequate pharmacological treatment was prescribed to 69·3%, of which 93·1% received α-adrenoceptor blockers. Regarding patients who were inappropriately treated, 53% did not receive any medication. Independent predictors of the prescription of a proper blockade were the diagnosis by endocrinologists [odds ratio (OR) 4·14; 95% confidence interval (CI), 2·51-6·85; P < 0·001], the presence of high blood pressure (OR 5·94; 95% CI, 3·11-11·33; P < 0·001) and the evidence of metastasis (OR 5·96; 95% CI, 1·93-18·46; P = 0·002). CONCLUSIONS: Although most patients received adequate pharmacological treatment, almost one-third were either not treated or received inappropriate medications. The diagnosis by endocrinologists, the presence of high blood pressure and the evidence of metastatic disease were identified as independent predictors of a proper blockade. These results highlight the need to educate physicians about the importance of starting adequate adrenoceptor blockade in all patients with hormonally functional PHAEO/PGL.
OBJECTIVE: Pharmacological treatment is mandatory in patients with hormonally functional phaeochromocytoma and paraganglioma (PHAEO/PGL). We evaluated if patients initially diagnosed with hormonally functional PHAEO/PGL by various medical subspecialties received proper adrenoceptor blockade, and analysed factors predicting the prescription of adequate treatment. METHODS: In a retrospective cohort study, we reviewed data from patients initially diagnosed with hormonally functional PHAEO/PGL outside the National Institutes of Health and Cedars-Sinai Medical Center, who were referred to these institutions between January 2001 and April 2015. Logistic regression was used to assess factors associated with proper adrenoceptor blockade. RESULTS: A total of 381 patients were included. Adequate pharmacological treatment was prescribed to 69·3%, of which 93·1% received α-adrenoceptor blockers. Regarding patients who were inappropriately treated, 53% did not receive any medication. Independent predictors of the prescription of a proper blockade were the diagnosis by endocrinologists [odds ratio (OR) 4·14; 95% confidence interval (CI), 2·51-6·85; P < 0·001], the presence of high blood pressure (OR 5·94; 95% CI, 3·11-11·33; P < 0·001) and the evidence of metastasis (OR 5·96; 95% CI, 1·93-18·46; P = 0·002). CONCLUSIONS: Although most patients received adequate pharmacological treatment, almost one-third were either not treated or received inappropriate medications. The diagnosis by endocrinologists, the presence of high blood pressure and the evidence of metastatic disease were identified as independent predictors of a proper blockade. These results highlight the need to educate physicians about the importance of starting adequate adrenoceptor blockade in all patients with hormonally functional PHAEO/PGL.
Authors: L Sibal; A Jovanovic; S C Agarwal; R T Peaston; R A James; T W J Lennard; R Bliss; A Batchelor; P Perros Journal: Clin Endocrinol (Oxf) Date: 2006-08 Impact factor: 3.478
Authors: Frederieke M Brouwers; Graeme Eisenhofer; Jacques W M Lenders; Karel Pacak Journal: Endocrinol Metab Clin North Am Date: 2006-12 Impact factor: 4.741
Authors: Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Hasan K Siddiqi; Hui-yu Yang; Amanda M Laird; Amy C Fox; Gerard M Doherty; Barbra S Miller; Paul G Gauger Journal: Surgery Date: 2012-12 Impact factor: 3.982
Authors: Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello Journal: Endocrine Date: 2013-07-02 Impact factor: 3.633
Authors: Henrique V Luiz; Run Yu; Katherine Wolf; Ning Miao; Andrew Mannes; Karel Pacak Journal: Clin Endocrinol (Oxf) Date: 2016-10-03 Impact factor: 3.478